The Fort Worth Press - Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

USD -
AED 3.672504
AFN 64.999972
ALL 81.827235
AMD 365.160186
ANG 1.789785
AOA 917.999929
ARS 1544.5379
AUD 1.462747
AWG 1.8
AZN 1.688498
BAM 1.762379
BBD 2.036128
BDT 126.028385
BGN 1.747831
BHD 0.381383
BIF 3024.210446
BMD 1
BND 1.292395
BOB 11.989636
BRL 5.583204
BSD 1.010945
BTN 95.007435
BWP 13.869176
BYN 3.0269
BYR 19600
BZD 2.033164
CAD 1.425785
CDF 2314.999965
CHF 0.832975
CLF 0.024992
CLP 983.610346
CNY 6.67035
CNH 6.667795
COP 3280.9
CRC 457.263359
CUC 1
CUP 24.260419
CVE 99.36917
CZK 22.014987
DJF 180.019916
DKK 6.747598
DOP 61.316908
DZD 136.867
EGP 53.550401
ERN 15
ETB 164.541452
EUR 0.90264
FJD 2.269205
FKP 0.753031
GBP 0.754265
GEL 2.602509
GGP 0.753031
GHS 11.838234
GIP 0.753031
GMD 74.000072
GNF 8956.017465
GTQ 7.724958
GYD 211.837332
HKD 7.842345
HNL 27.174457
HRK 6.76901
HTG 132.510848
HUF 329.346498
IDR 18246
ILS 3.177865
IMP 0.753031
INR 93.7175
IQD 1532.417211
IRR 1906075.000306
ISK 123.290099
JEP 0.753031
JMD 160.446988
JOD 0.708982
JPY 159.766972
KES 129.930115
KGS 87.449599
KHR 4122.94022
KMF 442.000179
KPW 899.999961
KRW 1328.424961
KWD 0.31126
KYD 0.842352
KZT 451.299842
LAK 22755.230323
LBP 90528.995629
LKR 335.972315
LRD 171.855991
LSL 16.573648
LTL 2.95274
LVL 0.60489
LYD 6.480393
MAD 9.86162
MDL 18.166334
MGA 4574.394744
MKD 55.551795
MMK 2099.724407
MNT 3604.903758
MOP 8.167515
MRU 40.781511
MUR 47.369683
MVR 15.400735
MWK 1752.977277
MXN 18.62714
MYR 4.0828
MZN 63.899323
NAD 16.571931
NGN 1345.720335
NIO 37.201087
NOK 9.569215
NPR 152.012581
NZD 1.800625
OMR 0.384498
PAB 1.010972
PEN 3.44501
PGK 4.540191
PHP 63.622501
PKR 277.574021
PLN 3.981599
PYG 6240.678409
QAR 3.685126
RON 4.824201
RSD 106.135997
RUB 83.077236
RWF 1495.696841
SAR 3.772213
SBD 8.090747
SCR 13.905119
SDG 601.501015
SEK 9.983398
SGD 1.28514
SHP 0.749316
SLE 22.901691
SLL 20969.504398
SOS 577.749741
SRD 37.645994
STD 20697.981008
STN 22.079133
SVC 8.845235
SYP 13001.999685
SZL 16.578126
THB 33.765962
TJS 9.290497
TMT 3.5
TND 3.012932
TOP 2.40776
TRY 50.257902
TTD 6.855598
TWD 32.987504
TZS 2658.884019
UAH 45.980237
UGX 4124.816943
UYU 40.90479
UZS 12104.528047
VES 900.490499
VND 25689.5
VUV 119.943861
WST 2.787799
XAF 592.09297
XAG 0.019407
XAU 0.000251330165
XCD 2.70255
XCG 1.821762
XDR 0.707052
XOF 592.09297
XPF 107.465645
YER 236.501711
ZAR 16.617706
ZMK 9001.183762
ZMW 20.597486
ZWL 321.999592
SSP 5786.523514
MXV 2.092395
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July

ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th

Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4

Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028

Text size:

NEWARK, CA / ACCESS Newswire / August 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.

"Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month," said Dinesh V. Patel, Ph.D., the Company's President and CEO. "Over the coming months, we look forward to the NDA filing of rusfertide for polycythemia vera, and advancing our wholly owned early-stage assets PN-881 and PN-477 into clinical and IND-enabling studies respectively."

Second Quarter 2025 Recent Developments and Upcoming Milestones

Rusfertide: Subcutaneous Injectable Hepcidin Mimetic for Polycythemia Vera (PV) and Other Blood Disorders

  • The full data set from the positive Phase 3 VERIFY trial of rusfertide in PV was presented during the prestigious plenary session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, June 1st.

  • The Company hosted an investor conference call on Monday, June 2nd discussing data shared during the plenary presentation. A replay of the call and accompanying presentation is available on the Company's Investor Relations Events and Presentations webpage here.

  • Rusfertide U.S. NDA filing for treatment of patients with PV, by partner Takeda Pharmaceuticals, expected in Q4 of this year.

Icotrokinra (JNJ-2113): Oral IL-23 Receptor Antagonist
  • On July 21st, the Company and its partner Johnson and Johnson announced the first icotrokinra NDA filing for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The application included data from four pivotal Phase 3 studies conducted as part of the ICONIC clinical development program, including ICONIC-LEAD, ICONIC-TOTAL and ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2.

  • On May 9th, data from the Phase 3 ICONIC-TOTAL study in difficult-to-treat scalp and genital psoriasis was presented at the Society for Investigative Dermatology Annual Meeting held in San Diego from May 7-10th.

    • On April 10th, data from the adolescent cohort of the Phase 3 ICONIC-LEAD study in moderate-to-severe plaque psoriasis was presented as a late-breaking abstract at the 2025 World Congress of Pediatric Dermatology (WCPD).

  • On March 10th, positive top line results from the Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) were announced. The full data set is scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th.

Development Pipeline:First-in-Class Oral IL-17 Peptide Antagonist (PN-881) & GLP-1, GIP, & GCG Triple Agonist (PN-477)
  • On June 30th, the Company hosted an investor call announcing the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. A replay of the call and accompanying presentation is available on the Company's Investor Relations Events and Presentations webpage here.

  • On May 9th, preclinical data on PN-881 was presented at the Society for Investigative Dermatology (SID) Annual Meeting held in San Diego from May 7-10th. Key takeaways from the pre-clinical characterization of the IL-17 oral peptide antagonist PN-881:

    • Potently and selectively binds IL-17A and -17F, blocking the three dimeric forms of the cytokine.

    • Nanomolar to picomolar in vitro potency comparable to bimekizumab and superior (70-fold) to secukinumab.

    • Metabolic stability in several matrices across several species, making it a suitable candidate for oral delivery.

    • Pharmocodynamic-based target engagement in a mouse IL-17 challenge model after oral dosing.

    • Dose-dependent efficacy with significant reduction in skin thickness in a 5-day rat IL-23 induced skin inflammation model after oral dosing.

Second Quarter 2025 Financial Results
  • Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June 30, 2025, were $673.0 million as compared to $559.2 million as of December 31, 2024.

Three Months Ended

Six Months Ended

June 30,

June 30,

(in thousands, except per share amounts)

2025

2024

2025

2024

(Unaudited)

License and collaboration revenue

$

5,546

$

4,167

$

33,867

$

259,120

Research and development expense

$

37,036

$

33,520

$

72,929

$

67,254

General and administrative expense

$

10,551

$

9,440

$

22,289

$

24,350

Net (loss) income

$

(34,771

)

$

(30,616

)

$

(46,426

)

$

176,724

Basic (loss) earnings per share

$

(0.55)

$

(0.50)

$

(0.73)

$

2.89

Diluted (loss) earnings per share

$

(0.55)

$

(0.50)

$

(0.73)

$

2.77

  • License and Collaboration Revenue:

    • License and collaboration revenue of $5.5 million and $4.2 million for the second quarter of 2025 and 2024, respectively, was comprised of development services we provided under the Takeda collaboration agreement.

    • License and collaboration revenue of $33.9 million for the six months ended June 30, 2025 was comprised of (i) proportional recognition of a $25 million milestone earned from Takeda in Q1 25, and (ii) development services we provided during the period. License and collaboration revenue of $259.1 million for the six months ended June 30, 2024 included (i) $254.1 million of the $300.0 million initial transaction price for the Takeda collaboration agreement allocated to the rusfertide license upon effectiveness of the agreement, and (ii) development services we provided during the period.

  • Research and Development ("R&D") Expense: The increases in R&D expense from the prior year periods were primarily due to increases in pre-clinical and drug discovery research expenses, including costs related to our new product candidates, IL-17 oral peptide antagonist PN-881 and obesity triple agonist peptide PN-477, partially offset by decreases in rusfertide expenses related to the Phase 3 VERIFY clinical trial.

  • General and Administrative ("G&A") Expense: The increase in G&A expense for the second quarter of 2025 from the prior year period was primarily due to increases in stock-based compensation and other personnel-related expenses. The decrease in G&A expense for the six months ended June 30, 2025 from the prior year period was primarily due to $4.6 million in advisory and legal fees recognized in 2024 related to the Takeda collaboration, partially offset by increases in stock-based compensation expense and other personnel-related expenses.

  • Net (Loss) Income: Net loss was $34.8 million, or $0.55 per basic and diluted share, for the second quarter of 2025 as compared to net loss of $30.6 million, or $0.50 per basic and diluted share, for the second quarter of 2024. Net loss was $46.4 million, or $0.73 per basic and diluted share, for the six months ended June 30, 2025 as compared to net income of $176.7 million, or $2.89 per basic share and $2.77 per diluted share, for the six months ended June 30, 2024, which included recognition of $259.1 million revenue related to the Takeda collaboration agreement upfront payment of $300.0 million.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July and an NDA submission for rusfertide expected by end of 2025. Icotrokinra (formerly, JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of icotrokinra and rusfertide, the timing of icotrokinra and rusfertide clinical trials, and timing of developments and announcements in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
[email protected]
+1 833 500 0061 ext 1

PROTAGONIST THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(Amounts in thousands except share and per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2025

2024

2025

2024

License and collaboration revenue

$

5,546

$

4,167

$

33,867

$

259,120

Operating expense:
Research and development (1)

37,036

33,520

72,929

67,254

General and administrative (1)

10,551

9,440

22,289

24,350

Total operating expense

47,587

42,960

95,218

91,604

(Loss) income from operations

(42,041

)

(38,793

)

(61,351

)

167,516

Interest income

7,406

7,404

14,979

11,780

Other income, net

36

97

118

78

(Loss) income before income tax expense (benefit)

(34,599

)

(31,292

)

(46,254

)

179,374

Income tax expense (benefit)

172

(676

)

172

2,650

Net (loss) income

$

(34,771

)

$

(30,616

)

$

(46,426

)

$

176,724

Net (loss) income per share, basic

$

(0.55

)

$

(0.50

)

$

(0.73

)

$

2.89

Net (loss) income per share, diluted

$

(0.55

)

$

(0.50

)

$

(0.73

)

$

2.77

Weighted-average shares used to compute net (loss) income per share, basic

63,510,537

61,305,289

63,238,682

61,080,489

Weighted-average shares used to compute net (loss) income per share, diluted

63,510,537

61,305,289

63,238,682

63,909,633

(1) Amount includes non-cash stock-based compensation expense.

Stock-based Compensation
(Unaudited, in thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2025

2024

2025

2024

Research and development

$

6,291

$

5,097

$

14,282

$

10,385

General and administrative

4,621

3,847

10,432

7,911

Total stock-based compensation expense

$

10,912

$

8,944

$

24,714

$

18,296

PROTAGONIST THERAPEUTICS, INC.
Selected Condensed Consolidated Balance Sheet Data
(Unaudited, In thousands)

June 30,

December 31,

2025

2024

Cash, cash equivalents and marketable securities$

672,958

$

559,165

Working capital

567,019

544,243

Total assets

718,006

744,725

Deferred revenue

20,063

30,567

Accumulated deficit

(386,948

)

(340,522

)

Total stockholders' equity

668,018

675,295

SOURCE: Protagonist Therapeutics



View the original press release on ACCESS Newswire

C.Rojas--TFWP